Unum Therapeutics

Unum Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's proprietary technology, called antibody-coupled T cell receptor (ACTR), is a universal, engineered cell therapy that is intended to be used in combination with a wide range of tumor-specific antibodies to target different tumor types. The company's product candidates are composed of ACTR T cells co-administered with approved and commercially available antibodies or antibodies in preclinical or clinical development.
  • TickerUMRX
  • ISINUS9032141049
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for UMRX

ValuEngine Rating and Forecast Report for UMRX

David Nierengarten ...
  • Jeffrey La Rosa

Initial Efficacy Reads Should Trigger Turnaround

David Nierengarten ...
  • Jeffrey La Rosa

Initial Efficacy Reads Should Trigger Turnaround

ValuEngine Rating and Forecast Report for UMRX

ValuEngine Rating and Forecast Report for UMRX

ValuEngine Rating and Forecast Report for UMRX

ValuEngine Rating and Forecast Report for UMRX

ValuEngine Rating and Forecast Report for UMRX

ValuEngine Rating and Forecast Report for UMRX

ValuEngine Rating and Forecast Report for UMRX

ValuEngine Rating and Forecast Report for UMRX

ValuEngine Rating and Forecast Report for UMRX

ValuEngine Rating and Forecast Report for UMRX

ResearchPool Subscriptions

Get the most out of your insights

Get in touch